Takeaways: Fabhalta gives Novartis a first‑in‑class, oral, mechanism‑targeted therapy in a tiny but high‑need C3G population, creating a premium niche nephrology revenue stream anchored on...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
Takeaways Bepirovirsen’s Canada filing signals a coming shift in the hepatitis B market from lifelong viral suppression to time‑limited “functional cure” regimens, which could reshape how p...
Takeaways: Pharmascience Canada has launched pms–Dolutegravir, becoming the only Canadian generic manufacturer with Health Canada authorization for dolutegravir tablets and adding a key HIV back...
Takeaways: Dr. Reddy’s has become the first company to secure Health Canada approval for a generic semaglutide injection (Ozempic equivalent), with an NOC covering 2 mg and 4 mg once‑weekly pens...
Takeaways: Health Canada’s software update effectively turns MiniMed 780G into a more flexible, next‑gen automated insulin delivery platform in Canada, now covering adults with t...
Takeaways: Bosaya and Vevzuo, layered on top of other recent denosumab biosimilar launches, should accelerate formulary switches and tender competition, strengthen Biocon’s credi...
Takeaways: AbbVie is doubling down on Canada as a discovery hub by becoming the founding sponsor of BioLabs University of Toronto, a ~40,000 sq. ft shared lab at MaRS t...
Takeaways: Health Canada has authorized PrUpgolyv (golimumab injection), giving Canada its first Simponi biosimilar and further extending JAMP Pharma’s BioJAMP immunolo...
Takeaways VUEWAY should help Bracco win share in Canada’s MRI contrast market by offering radiology departments a lower‑gadolinium option that still delivers high‑quality images, which is increa...
